New drug combo shows promise for Tough-to-Treat head and neck cancer

NCT ID NCT05523323

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Mar 14, 2026 · Last updated May 08, 2026 · Updated 4 times

Summary

This study tested whether adding lenvatinib to pembrolizumab helps people with advanced head and neck cancer that has come back or spread. 112 adults with a specific marker (PD-L1 positive) received either the drug combo or pembrolizumab alone. The goal was to see if the combination shrinks tumors more, delays cancer growth, or extends survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Anhui Cancer Hospital-Radiology Department ( Site 3333)

Hefei, Anhui, 230031, China
Beijing Cancer Hospital ( Site 3314)

Beining, Beijing Municipality, 100036, China
Beijing Tongren Hospital affiliated to Capital Medical University ( Site 3343)

Beijing, Beijing Municipality, 100730, China
Changzhou Tumor Hospital - Changzhou Fourth People's Hospital ( Site 3339)

Changzhou, Jiangsu, 213000, China
Chongqing Cancer Hospital ( Site 3327)

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center ( Site 3324)

Shanghai, Shanghai Municipality, 200032, China
Fujian Provincial Cancer Hospital ( Site 3326)

Fuzhou, Fujian, 350014, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 3322)

Nanning, Guangxi, 530000, China
Guizhou Cancer Hospital ( Site 3330)

Guiyang, Guizhou, 550003, China
Henan Cancer Hospital ( Site 3309)

Zhengzhou, Henan, 450008, China
Hunan Cancer Hospital ( Site 3311)

Changsha, Hunan, 410000, China
Hunan Cancer Hospital ( Site 3334)

Changsha, Hunan, 410013, China
Jiangxi Cancer Hospital ( Site 3313)

Nanchang, Jiangxi, 330029, China
Jilin Cancer Hospital ( Site 3310)

Changchun, Jilin, 130000, China
Peking Union Medical College Hospital ( Site 3304)

Bejiing, Beijing Municipality, 100032, China
Shanghai 9th People hospital ( Site 3332)

Shanghai, Shanghai Municipality, 200011, China
Shanghai East Hospital ( Site 3300)

Shanghai, Shanghai Municipality, 200120, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3336)

Guangzhou, Guangdong, 510000, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3338)

Guangzhou, Guangdong, 510000, China
The First Affiliated Hospital of Xi an Jiaotong University ( Site 3328)

Xi'an, Shaanxi, 710000, China
The First Affiliated Hospital, Sun Yat-sen University ( Site 3344)

Guangzhou, Guangdong, 510080, China
The Third Affiliated Hospital of Harbin Medical University ( Site 3302)

Harbin, Heilongjiang, 150081, China
Tianjin Medical University Cancer Hospital ( Site 3312)

Tianjin, Tianjin Municipality, 300060, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 3316)

Wuhan, Hubei, 430030, China
West China Hospital of Sichuan University ( Site 3308)

Chengdu, Sichuan, 610047, China
Wuhan Union hospital Cancer Center ( Site 3307)

Wuhan, Hubei, 430000, China
Xiangya Hospital of Central South University ( Site 3305)

Changsha, Hunan, 410008, China
Zhejiang Cancer Hospital ( Site 3303)

Hangzhou, Zhejiang, 310022, China

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD-AND-NECK SQUAMOUS CELL CARCINOMA